Russian Heart Failure Journal 2008year Microalbuminuria is a universal marker of unfavorable prognosis


To access this material please log in or register

Register Authorize
2008/

Microalbuminuria is a universal marker of unfavorable prognosis

Mukhin N.A., Fomin V.V., Moiseev S.V., Nanchikeeva M.L.

Keywords:

DOI:

Review focuses on pathogenetic aspects of microalbuminuria (MAU). Data from recent clinical studies are presented, which have demonstrated that MAU is a marker of high probability for both impairment of renal function and development of life-threatening cardiovascular complications. Therefore regular examination for the presence of MAU is desirable for all individuals at high or very high risk of cardiovascular complications and those who have essential AH, IHD or CHF.
    1.    Мухин Н. А., Моисеев В. С., Кобалава Ж. Д. и др. Кардио-ренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Терапевтический архив. 2004; 76 (6):39–46.
    2.    De Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004; 66 (6):2109–2118.
    3.    European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003 Jun; 21 (6):1011–1053.
    4.    Секция артериальной гипертонии ВНОК. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). http://webmed.irkutsk.ru / doc / pdf / ah.pdf
    5.    Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007; 25 (9):1751–1762.
    6.    Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens. 1998; 16 (9):1325–1333.
    7.    Schrader J, Luders S, Kulschewski A et al. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study). J Hypertens. 2006; 24 (3):541–548
    8.    Pedrinelli R, Giampietro O, Carmassi F et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet. 1994; 344 (8914):14–18.
    9.    Ochodnicky P, Henning RH, van Dokkum RP, de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. Cardiovasc Pharmacol. 2006; 47 (Suppl 2):S151‑S162.
    10.    Gerber LM, Shmukler C, Alderman MH. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and nonwhite subjects. Arch Intern Med. 1992; 152 (2):373–377.
    11.    Tsakiris A, Doumas M, Lagatouras D et al. Microalbuminuria is determined by systolic and pulse pressure over a 12‑year period and related to peripheral artery disease in normotensive and hypertensive subjects: the Three Areas Study in Greece (TAS-GR). Angiology. 2006; 57 (3):313–320.
    12.    Metclaf P, Baker J, Scott A et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension and hyperlipidemia. Clin Chem. 1992; 38 (9):1802–1808.
    13.    Redon J, Miralles A, Pascual JM et al. Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. J Hypertens. 1997; 15 (1):79–86.
    14.    Shankar SS, Steinberg HO. Obesity and endothelial dysfunction. Semin Vasc Med. 2005; 5 (1):56–64.
    15.    Сагинова Е. А., Федорова Е. А., Фомин В. В. и др. Формирование поражения почек у больных ожирением. Терапевтический архив. 2005; 77 (5):36–41.
    16.    Lee JE, Kim YG, Choi YH et al. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006; 47 (5): 962–967.
    17.    Farquharson CAJ, Butler R, Hill A et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002; 106 (2):221–226.
    18.    Lekatsas I, Koulouris S, Triantafyllou K et al. Prognostic significance of microalbuminuria in non-diabetic patients with acute myocardial infarction. Int J Cardiol. 2006; 106 (2):218–223.
    19.    Szczudlik A, Turaj W, Slowik A, Strojny J. Microalbuminuria and hyperthermia independently predict long-term mortality in acute ischemic stroke patients. Acta Neurol Scand. 2003; 107 (2):96–101.
    20.    Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol. 1999; 19 (8):1992–1997.
    21.    Yuyun MF, Khaw KT, Luben R et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol. 2004; 159 (3):284–293.
    22.    Cerasola G, Cottone S, Mule G et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens. 1996; 14 (7):915–920.
    23.    Lieb W, Mayer B, Stritzke J et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: The MONICA / KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant. 2006; 21 (10):2780–2787.
    24.    Wachtell K, Palmieri V, Olsen MH et al. Urine albumin / creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction. Am Heart J. 2002; 143 (2):319–326.
    25.    Torun D, Sezer S, Arat Z et al. The frequency of combined target organ damage and the beneficial effect of ambulatory blood pressure monitoring in never treated mild-to-moderate hypertensive patients. Int Heart J. 2005; 46 (6):1073–1082.
    26.    Munakata M, Nunokawa T, Yoshinaga K et al. Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension – a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). Hypertens Res. 2006; 29 (7): 515–521.
    27.    Furtner M, Kiechl S, Mair A et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur Heart J. 2005; 26 (3):279–287.
    28.    Cottone S, Mule G, Nardi E et al. Microalbuminuria and early endothelial activation in essential hypertension. J Hum Hypertens. 2007; 21 (2):167–172.
    29.    Dell’Omo G, Penno G, Giorgi D et al. Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive men. Am J Kidney Dis. 2002; 40 (1):1–8.
    30.    Graninger M, Reiter R, Drucker C et al. Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol. 2004; 44 (3):335–339.
    31.    Delles C, Schmieder RE. Renal endothelial effects of antihypertensive therapy. Curr Opin Nephrol Hypertens. 2004; 13 (5):489–493.
    32.    The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355 (9200):253–259.
    33.    Diercks GF, Janssen WM, van Boven AJ et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol. 2000; 86 (6):635–638.
    34.    Asselbergs FW, Diercks GFH, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004; 110 (18):2809–2816.
    35.    Hillege HL, Janssen WM, Bak AA et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001; 249 (6):519–526.
    36.    Tsioufis C, Dimitriadis K, Taxiarchou E et al. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens. 2006; 19 (5):462–466.
    37.    Pedrinelli R, Dell’Omo G, Di Bello V et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol. 2004; 24 (12):2414–2419.
    38.    Kistorp C, Raymond I, Pedersen F et al. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005; 293 (13):1609–1616.
    39.    de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. JJ Am Soc Nephrol. 2006; 17 (8):2100–2105.

To access this material please log in or register

Register Authorize
Ru En